Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of nipocalimab in active idiopathic inflammatory myopathies
2021-005202-98Phase 2Active
- Sponsor
- Janssen Pharmaceutical
- Start
- Jul 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Autoimmune Myopathies comparing Nipocalimab with Placebo (2 arms). Primary endpoint: Minimal improvement on IMACS TIS with low-dose prednisone. Started Jul 2022; status: active.
02
Drugs
nipocalimab
03
Conditions
Autoimmune Myopathies
Beyond the preview
Go deeper on 2021-005202-98.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-005202-98.